Esperion Theraptc Cm (ESPR) 10.98 $ESPR Looking Into

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Esperion Theraptc Cm (ESPR) 10.98 $ESPR

Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 10.98 (+0.12)

Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 10.98 (+0.12)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 10.98 (+0.12), CMRX: 4.08 (+0.09), GERN: 2.71 (+0.03), CYTX: 2.17 (unch), CLDX: 4.67 (+0.05), SGMO: 6.61 (+0.28), PTCT: 6.10 (+0.13), ATHX: 2.17 (-0.05), MNKD: 1.02 (+0.03)

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors
PR Newswire Europe - Wed Mar 23, 7:01AM CDT
- Mr. Wiklund is a well recognized and seasoned healthcare executive
ESPR: 10.98 (+0.12)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 10.98 (+0.12), VCEL: 2.22 (-0.04), SGMO: 6.61 (+0.28), ZYNE: 9.20 (+0.36)

INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 11, 8:35PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company" (Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 10.98 (+0.12)

March 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Fri Mar 11, 8:30AM CST
Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period". Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
ESPR: 10.98 (+0.12)

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 is Last Day to File Lead Plaintiff Papers in Esperion Therapeutics (ESPR) Securities Case
GlobeNewswire - Wed Mar 09, 7:45PM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 10.98 (+0.12)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Wed Mar 09, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company" (Nasdaq: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period". Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 10.98 (+0.12)

Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
ESPR: 10.98 (+0.12)

Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion Therapeutics, Inc.
BusinessWire - Tue Mar 08, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM" reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company" (Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period". Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.
ESPR: 10.98 (+0.12)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
PR Newswire - Tue Mar 08, 8:52AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 10.98 (+0.12)

Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case
BusinessWire - Mon Mar 07, 10:39AM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 10.98 (+0.12)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Mon Mar 07, 9:01AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company" (NASDAQ: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period". Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 10.98 (+0.12)

Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Mon Mar 07, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 10.98 (+0.12)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016
BusinessWire - Wed Feb 10, 1:14PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 10.98 (+0.12)

ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
BusinessWire - Tue Feb 09, 4:09PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased the common stock of Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NASDAQ:ESPR) between August 18, 2015 and September 28, 2015, inclusive (the "Class Period".
ESPR: 10.98 (+0.12)

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
PR Newswire - Tue Feb 09, 11:43AM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. ("Esperion" or the "Company" (NasdaqGM:ESPR) of the March 14, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
ESPR: 10.98 (+0.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 46

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 136

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 123

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading

Top 5 Most Recently Viewed Articles

Wicked Cutz, Cinnabon Team Up for Bacon Jerky Debut

Updated Category News Views 13

Ever thought you'd see the day when your protein snack could taste like a cinnamon roll? Well, folks, that day has arrived. Wicked Cutz, a force in the meat snack industry, and Cinnabon, the undisputed champs of cinnamon rolls, have rolled out a product that's bound to raise some eyebrows: bacon jerky with a sweet pastry twist. Why Bacon Jerky? You might be wondering, why...

Continue Reading
10 High-Yielding Small-Cap Stocks Under $15 in 2024

Updated Category Stocks Views 542

In the ever-evolving landscape of the stock market, small-cap stocks can be a gold mine for investors seeking high yields without breaking the bank. As we navigate through 2024, let's delve into a curated list of 10 small-cap stocks trading under $15 that offer attractive dividend yields. But remember, high yields can be as enticing as they are perilous, so tread with...

Continue Reading
Frazier Life Sciences Secures Over $630M for Growth Initiatives

Updated Category News Views 239

Frazier Life Sciences (FLS) raised over $630 million back in 2024, which got everyone buzzing on the trading floor. This wasn't just pocket change; it came from an oversubscribed fundraise that saw new and existing investors jumping on board like it was Black Friday. Talk about a cash infusion! The Public Fund has amassed around $1.7 billion since its launch three years...

Continue Reading
1847 Holdings LLC Achieves Milestone with $11.1M Offering

Updated Category News Views 112

1847 Holdings LLC Successfully Completes Public Offering 1847 Holdings LLC (NYSE American: EFSH), a company dedicated to investing in high-potential middle-market businesses, recently announced an exciting achievement. The firm has successfully closed its public offering, resulting in gross proceeds of $11.1 million. This accomplishment reflects the company's continued...

Continue Reading
Live Nation Entertainment's Stock Analysis Amid Sell-Off

Updated Category News Views 238

Understanding Live Nation Entertainment's Recent Stock Movements The trading landscape for Live Nation Entertainment, Inc. (LYV) has seen quieter activity following a significant sell-off of 6.5%. Investors and market analysts are closely observing whether this stock will continue its downward trajectory. Technical Analysis: Support and Resistance Levels Identifying Key...

Continue Reading